European Commission logo
English English
CORDIS - EU research results
CORDIS

Development of carbohydrate based anticancer agents

Objective

CarboMed will assess the commercial viability of targeting cancer cell glycosylation as a next-generation therapeutic strategy to treat cancer in the clinic. Carbohydrates (glycans) coat the cell of every organism. The glycosylation pattern of cancer cells is, however, very different from that of healthy cells and is associated with aggressive and invasive forms of cancers. By combining our knowledge on carbohydrate chemistry and cancer immunology we targeted the cancer-cell protecting carbohydrate coat, hampering the cancer's ability to grow and metastasize. In this project, we aim to deliver a technical and commercial proof-of-concept for targeting the glycosylation of cancer cells to ultimately enable clinical studies

Host institution

STICHTING RADBOUD UNIVERSITEIT
Net EU contribution
€ 150 000,00
Address
HOUTLAAN 4
6525 XZ Nijmegen
Netherlands

See on map

Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)